Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

NCT04989153 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2021-08-04

No results posted yet for this study

Summary

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.

Conditions

Interventions

DIAGNOSTIC_TEST

pepsinogen

serum pepsinogen diagnosed gastric cancer and precanceous lesion

Sponsors & Collaborators

  • Jilin City People's Hospital

    collaborator UNKNOWN
  • No. 924 Hospital of the People's Liberation Army of China

    collaborator UNKNOWN
  • Kunshan Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Chinese PLA General Hospital

    collaborator OTHER
  • Sichuan Provincial People's Hospital

    collaborator OTHER
  • Affiliated Hospital of Southwest Medical University

    collaborator OTHER
  • Zhongshan Hospital Xiamen University

    collaborator OTHER
  • Jingzhou Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Changhai Hospital

    collaborator OTHER
  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Yi Zhao, Master · 2nd affiliated hospital of Zhejiang university, school of medicine

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-05
Primary Completion
2022-12-31
Completion
2023-12-06

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04989153 on ClinicalTrials.gov